Glaxo stokes triple-combo hopes with data topping AZ's Symbicort - FiercePharma
FiercePharmaGlaxo stokes triple-combo hopes with data topping AZ's SymbicortFiercePharmaMonday, the company announced that the pipeline med had nailed both of its primary endpoints in a Phase III study, topping rival Symbicort from AstraZeneca on metrics measuring lung function and health-related quality of life.
Triple Combination Therapy Shows Promise in COPD; Superior to Symbicort/Turbohaler Therapies - COPD News Today
COPD News TodayTriple Combination Therapy Shows Promise in COPD; Superior to Symbicort/Turbohaler TherapiesCOPD News TodayFULFIL is a randomized, double-blind, multicenter study designed to evaluate the efficacy and safety of a daily dose of the FF/UMEC/IV triple therapy vs.
AstraZeneca's Growth Platform Includes Symbicort, Pulmicort - Market Realist
Market RealistAstraZeneca's Growth Platform Includes Symbicort, PulmicortMarket RealistAstraZeneca's (AZN) respiratory, inflammation, and autoimmunity (or RI&A) segment is included in the company's growth platform and a key focus area for development.
Can GlaxoSmithKline plc (ADR) Subsist Advair's Patent Expiry - Business Finance News
Business Finance NewsCan GlaxoSmithKline plc (ADR) Subsist Advair's Patent ExpiryBusiness Finance NewsThe main competitor of GSK's respiratory franchise is AstraZeneca's plc (ADR) (NYSE:AZN) Symbicort.